Our findings pave the way for future therapeutic strategies aimed at inhibiting KCTD17 or restoring SERPINA3 expression to combat liver fibrosis in patients with MASH. The gene discussed is KCTD17; the disease is metabolic dysfunction-associated steatohepatitis.